Skip to main
EVAX

EVAX Stock Forecast & Price Target

EVAX Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Evaxion AS has demonstrated significant progress in its proprietary AI platform, AI-Immunology, with the prediction accuracy of its PIONEER model showing an improvement to 81% in identifying immunogenic neoantigens, bolstering the potential efficacy of its cancer immunotherapy, EVX-01. The latest clinical data highlights a 75% overall response rate (ORR) for EVX-01 in combination with pembrolizumab, reflecting an increase from the previous year's 69% and positioning the company favorably compared to its competitors in the neoantigen cancer vaccine sector. If forthcoming data continues to support these positive trends, it may serve as a catalyst for securing strategic partnerships aimed at advancing Evaxion’s late-stage development and commercialization efforts.

Bears say

Evaxion AS's stock has faced negative market reactions despite strong data updates for its EVX-01 product, which suggests that investor expectations for a definitive indication of EVX-01’s contribution are not being met. This disconnect indicates a potential lack of confidence in the company's ability to deliver clear, convincing progress in their oncology pipeline, which could hinder future stock performance. Additionally, the call to accumulate shares during periods of weakness may reflect broader concerns about the company's financial stability and market position, potentially deterring investors looking for stronger, more consistent growth indicators.

EVAX has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Evaxion Biotech A/S and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Evaxion Biotech A/S (EVAX) Forecast

Analysts have given EVAX a Strong Buy based on their latest research and market trends.

According to 4 analysts, EVAX has a Strong Buy consensus rating as of Mar 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Evaxion Biotech A/S (EVAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.